The study was published online in JAMA Neurology on March 31, 2025.

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

Approximately 45% of ischemic strokes are caused by small or large artery thrombus, 20% are embolic in origin, and others have an unknown cause (Hickey, 2003). Thrombosis can form in the ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

Generic Xarelto is a blood thinner medicine that lowers blood clotting. Aurobindo has obtained the Food and Drug ...

Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Daniel Davis to its Board of ...

Imperative Care, Inc. today announced it will fund an investigator-initiated, multicenter, randomized, controlled clinical trial comparing aspiration thrombectomy with the Zoom Stroke System plus best ...

The birth of a child is typically the happiest day in a parent's life. But for a Minneapolis family, it started a mother's ...

Aurobindo Pharma jumped 3.42% to Rs 1,119.55 after the pharma company said that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban ...

Aurobindo Pharma gains FDA approval to manufacture and market Rivaroxaban Tablets USP, with plans to launch by June.

Aurobindo Pharma said that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg.